SCHEMBL866713

SCHEMBL866713

CCC(O)c1ccccc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 2/20 0.59
ADRB1 P08588 2/20 0.59
AOC3 Q16853 1/20 0.59
CYP2D6 P10635 2/20 0.58
NFKB1 P19838 1/20 0.58
HIF1A Q16665 1/20 0.58
BLM P54132 1/20 0.56
LMNA P02545 1/20 0.50
CASP1 P29466 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NISCH Q9Y2I1 1/20 0.44
TSHR P16473 1/20 0.42
RECQL P46063 1/20 0.39
ACP3 P15309 1/20 0.39
ALDH1A1 P00352 1/20 0.39
SLC6A2 P23975 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14665090 1.00 ADRB2 (0.59) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL16064818 1.00 ADRB2 (0.59) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL31521481 1.00 ADRB2 (0.59) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL5107133 0.84 LMNA (0.61) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL5107136 0.84 LMNA (0.61) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL5107130 0.84 LMNA (0.61) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL30172716 0.84 LMNA (0.61) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL16070801 0.83 CYP2D6 (0.52) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL5693670 0.83 ADRB2 (0.56) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL6680491 0.82 ADRB2 (0.54) ADRB2ADRB1AOC3CYP2D6NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117568296-A P450 hydroxylase mutant and synthetic R-halohydrin thereof 遵义医科大学 2024-02-20 CN disclosed
CN-108383703-B 3' -chlorophenylpropanol synthesis process 兰州紫东药业有限公司 2021-08-03 CN disclosed
EP-2968211-B1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO PHARM SOLUTIONS CO LTD (KR) 2021-05-12 EP disclosed
EP-2527314-B1 Process for preparation of phenyl carbamate derivatives BIO-PHARM SOLUTIONS CO LTD (KR) 2017-10-04 EP disclosed
EP-2797878-B1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING STROKE BIO-PHARM SOLUTIONS CO LTD (KR) 2017-08-16 EP disclosed
EP-2797880-B1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY BIO-PHARM SOLUTIONS CO LTD (KR) 2017-03-01 EP disclosed
CN-102442974-B Camphor derivative compound, and production method and use thereof WANG BINGJUN 2014-07-23 CN disclosed
US-8609839-B2 Camphor-derived compounds, method for manufacturing the same, and application thereof NATIONAL TSING HUA UNIVERSITY (TW) 2013-12-17 US disclosed
US-8362020-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
EP-1813613-B1 NOVEL FUSED IMIDAZOLE DERIVATIVE MSD KK (JP) 2012-12-19 EP disclosed
US-20080103136-A1 Novel Fused Imidazole Derivative MSD K.K. (JP) 2008-05-01 US disclosed
CN-101098870-A Novel fused imidazole derivative BANYU PHARMA CO LTD (JP) 2008-01-02 CN disclosed
EP-1813613-A1 NOVEL FUSED IMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-01 EP disclosed
EP-1505156-B1 Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester CONSORTIUM ELEKTROCHEM IND (DE) 2005-12-07 EP disclosed
EP-0985649-B1 Method for producing an aromatic compound having an alkyl group with at least three carbon atoms TORAY INDUSTRIES (JP) 2004-11-24 EP disclosed
US-6462248-B1 THROUGH CONVERSION, ISOMERIZATION AND/OR ADSORPTIVE SEPARATION OF AROMATIC COMPOUNDS TORAY INDUSTRIES, INC. (JP) 2002-10-08 US disclosed
EP-0985649-A2 Method for producing an aromatic compound having an alkyl group with at least three carbon atoms TORAY INDUSTRIES, INC. (JP) 2000-03-15 EP disclosed
EP-0414686-B1 DERIVATIVES OF TRIFLUOROMETHYL-1-TETRALINES, PREPARATION AND APPLICATION THEREOF FOR THE SYNTHESIS OF COMPOUNDS HAVING THERAPEUTIC PROPERTIES LABORATOIRES LUCIEN (FR) 1993-09-22 EP disclosed
EP-0414686-A1 DERIVATIVES OF TRIFLUOROMETHYL-1-TETRALINES, PREPARATION AND APPLICATION THEREOF FOR THE SYNTHESIS OF COMPOUNDS HAVING THERAPEUTIC PROPERTIES. LUCIEN LAB (FR) 1991-03-06 EP disclosed
WO-1989004819-A1 DERIVATIVES OF TRIFLUOROMETHYL-1-TETRALINES, PREPARATION AND APPLICATION THEREOF FOR THE SYNTHESIS OF COMPOUNDS HAVING THERAPEUTIC PROPERTIES LABORATOIRES LUCIEN (FR) 1989-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103136-A1 Novel Fused Imidazole Derivative HRH4, H1-4, H1-3 ADRB2 887/4885ADRB1 828/4885AOC3 580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.